Immunotherapy may replace chemo in head and neck cancer treatment
NCT ID NCT03383094
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This study compares two treatments for people with advanced p16-positive head and neck cancer. One group gets radiation plus the immunotherapy drug pembrolizumab (Keytruda), while the other gets radiation plus standard chemotherapy. The goal is to see if the immunotherapy approach works as well or better with fewer side effects. About 126 participants will be followed to track cancer progression and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center & Research Facility
Tampa, Florida, 33612, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37203, United States
-
Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.